All guides

Is BPC-157 legal in the U.S.? Status as of October 2026

BPC-157 is the most searched recovery peptide and the one with the most confusing legal status. The short version: as of October 2026 no licensed U.S. pharmacy can compound it, and buying it online is buying an unapproved drug.

Why it cannot be prescribed

Licensed pharmacies may only compound substances FDA has placed on its 503A bulks list. In 2023 FDA placed BPC-157 in Category 2, which blocks compounding, citing safety concerns and lack of human data. In July 2026 an FDA advisory panel voted to recommend BPC-157 and five other peptides for the list. FDA has not acted on that recommendation. Until it does, the status is unchanged.

The “research use only” problem

Websites selling BPC-157 “for research purposes” and “not for human consumption” have been the main source for consumers. In August 2026 FDA sent warning letters to five such sellers, stating that the disclaimer does not control when the rest of the site, including bundled bacteriostatic water and dosing calculators, shows intended human use. Those products are unapproved, misbranded drugs with no verified purity, sterility, or dose. We do not sell or link to them.

What a clinician can offer today

For soft-tissue recovery, clinicians can prescribe compounded glutathione or NAD+ (not FDA-approved, limited evidence) and, more importantly, build the evidence-backed foundation: sleep, protein, collagen with vitamin C, omega-3s, load management, and physical therapy.

We will update this page the day FDA changes the status.

Sources

Read next

Talk to a licensed clinician in your state.

Tell us your state and goal. We match you with a vetted provider licensed where you live and show the monthly price first. The clinician decides what, if anything, is right for you.

Find a provider in my state
Ask a questionAnswers with sources. No dosing.

Ask how GLP-1 or peptide therapy works, what it costs, or what a holistic protocol around it looks like.

Find a provider in my state